Apogee Therapeutics, Inc. (NASDAQ: APGE) has captured the attention of investors with its robust pipeline in the biotechnology sector, focusing on innovative treatments for various inflammatory and immunological conditions. Despite being a relatively young company, incorporated in 2022 and headquartered in Waltham, Massachusetts, Apogee is making significant strides in the healthcare industry.

Currently trading at $69.91, Apogee’s stock has shown resilience with a 52-week range of $28.79 to $82.43, demonstrating a strong performance in the market. The stock’s current price is just a fraction below its 50-day moving average of $73.63 but significantly above its 200-day moving average of $52.45, indicating a positive trend over…